• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Palvella Therapeutics, Inc. - Common Stock (NQ:PVLA)

    151.40 +0.85 (+0.56%)
    Streaming Delayed Price Updated: 12:48 PM EDT, Sep 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Palvella Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 Next >
    News headline image
    Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands ↗
    Palvella Therapeutics (NASDAQ:PVLA) is advancing topical therapies for serious rare skin diseases and vascular malformations that lack FDA-approved treatments, with its lead candidate, QTORIN... 
    Via MarketBeat
    News headline image
    Palvella (PVLA) Q2 2026 Earnings Call Transcript ↗
    Rare skin disease biotech reports $250.6M cash, plans 2027 FDA approval for lead therapy. 
    Via The Motley Fool
    Topics Earnings
    Palvella Therapeutics (NASDAQ:PVLA) Reports Wider Q1 Loss but NDA Submission Stay on Track ↗
    Via Chartmill
    News headline image
    Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Q2 Earnings Call Highlights ↗
    Palvella Therapeutics (NASDAQ:PVLA) said it remains on track to complete its new drug application submission for QTORIN rapamycin in microcystic lymphatic malformations, or mLM, during the second half... 
    Via MarketBeat
    Topics Earnings
    News headline image
    Full Transcript: Palvella Therapeutics Q2 2026 Earnings Call ↗
    Palvella Therapeutics (NASDAQ:PVLA) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For... 
    Via Benzinga
    News headline image
    Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally ↗
    Focused on rare skin disease therapies, this clinical-stage biotech just reported a notable insider sale amid a year of sharp stock gains. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    FDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Q1 Earnings Call Highlights ↗
    Palvella Therapeutics (NASDAQ:PVLA) said it remains on track to submit a New Drug Application in the second half of 2026 for QTORIN rapamycin in Microcystic Lymphatic Malformations, after reporting... 
    Via MarketBeat
    Topics Earnings
    News headline image
    Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.